FBLG Stock Analysis: Buy, Sell, or Hold?
FBLG - FibroBiologics, Inc. Common Stock
$1.44
0.15 (11.63%)
▲
5d:
+35.85%
30d:
+95.79%
90d:
+37.14%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When FBLG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: FBLG is 28.6% above its trading range ($1.12). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: FBLG is 28.6% above its trading range ($1.12). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: FBLG is currently trading at $1.44, which is considered extended relative to its 30-day fair value range of $0.70 to $1.12.
Technical Outlook: Technically, FBLG is in a strong downtrend. Immediate support is located at $0.95, while resistance sits at $1.49. The stock is showing strong short-term momentum, up 11.6% recently.
Market Sentiment: FBLG scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.50 (+768.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FBLG is in a strong downtrend. Immediate support is located at $0.95, while resistance sits at $1.49. The stock is showing strong short-term momentum, up 11.6% recently.
Market Sentiment: FBLG scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.50 (+768.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.70 -
$1.12
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+28.6% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+11.6%)
- BULLISH: Trading 768.1% below Wall St target ($12.50)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.70 -
$1.12
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.95
Resistance Level
$1.49
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.47
Wall Street Target
$12.50
(+768.1%)
Share & Embed Analysis
Last updated: August 24, 2026 7:06 AM ET
Data refreshes hourly during market hours. Next update: 8:06 AM
Data refreshes hourly during market hours. Next update: 8:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FBLG showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Hamid Khoja
BUY
1500 shares
2026-03-04
Pete O'heeron
BUY
793 shares
2026-03-04
Pete O'heeron
BUY
910 shares
2026-03-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 35 SELL |
